![N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6- dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (SGC) for the treatment of cardiovascular diseases](/docs/US/2018-12-11/US10150773B2/abs.jpg.600x600.jpg)
- 专利标题： N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6- dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (SGC) for the treatment of cardiovascular diseases
-
申请号： US15548310申请日： 2016-02-02
-
公开(公告)号： US10150773B2公开(公告)日： 2018-12-11
- 发明人: Alexandros Vakalopoulos , Damian Brockschnieder , Frank Wunder , Johannes-Peter Stasch , Tobias Marquardt , Lisa Dietz , Min Jian Volkhart Li
- 申请人： Bayer Pharma Aktiengesellschaft
- 申请人地址： DE Berlin
- 专利权人： Bayer Pharma Aktiengesellschaft
- 当前专利权人： Bayer Pharma Aktiengesellschaft
- 当前专利权人地址： DE Berlin
- 代理机构： Ice Miller LLP
- 优先权： EP15153959 20150205
- 国际申请： PCT/EP2016/052123 WO 20160202
- 国际公布： WO2016/124564 WO 20160811
- 主分类号： C07D487/04
- IPC分类号： C07D487/04 ; A61K31/4985 ; A61K31/695 ; A61K45/06 ; C07B59/00 ; C07F7/08
![N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6- dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (SGC) for the treatment of cardiovascular diseases](/abs-image/US/2018/12/11/US10150773B2/abs.jpg.150x150.jpg)
摘要：
The present application relates to novel substituted imidazo[1,2-a]pyrazine carboxamides of general formula (I) to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
公开/授权文献
信息查询
